July 13, 2005 After four days in a row of higher prices, biotech booked a small loss today, but remained close to its 2005 high. The Centient Biotech 200 was lower by 8 points at 3533.03, a loss of .22%. Genentech will raise $2 billion in notes for various corporate projects, asthma medicines from GlaxoSmithKline and Novartis went up before an FDA advisory panel, Boston Scientific continues to have problems with its stents, Able Labs was falsifying test documents of its medications, prompting the shutdown of its operations, Pfizer will cut one-third of its German work force, aaiPharma sold its pharmaceutical assets in its bankruptcy, and Lilly extended a collaboration with Structural Genomix. More details...
